Measuring Biomarkers
at Every Stage
of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way researchers, academics and drug manufacturers measure and detect various forms of cancer at the earliest stage. Quanterix' focus in oncology is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's application in oncology by exploring our scientific publications and journals.

Latest News

Kjaer IM, Olsen DA, Brandslund I, Bechmann T, Jakobsen EH, Bogh SB and Madsen JS Sci Rep. 2020 Apr 21;10(1):6714 DOI: https://doi.org/10.1038/s41598-020-63375-z Abstract
Grit JL, Pridgeon MG, Essenburg CJ, Wolfrum E, Madaj ZB, Turner L, Wulfkuhle J, Petricoin EF, Graveel CR and Steensma MR Genes 2020, 11(3), 331 DOI: https://doi.org/10.3390/genes11030331 Abstract

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more